Welcome to our dedicated page for TRANSLATE BIO news (Ticker: TBIO), a resource for investors and traders seeking the latest updates and insights on TRANSLATE BIO stock.
Telesis Bio Inc. develops DNA and mRNA synthesis solutions for therapeutic discovery, using automated systems and enzymatic synthesis technology that support on-site biofoundry workflows. Company news centers on the Gibson SOLA platform, BioXp systems, mRNA synthesis offerings, and customer adoption in areas such as biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy.
Recurring updates also include licensing agreements, laboratory automation collaborations, private financing activity, financial results, restructuring effects, and capital-market actions such as reverse stock splits and trading-status changes. The company has described a commercial focus on Gibson SOLA and BioXp mRNA solutions while reporting product, collaboration, service, and royalty revenue categories.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Telesis Bio Inc. (NASDAQ: TBIO) announced the expansion of its BioXp® Select Kit product line with two new kits for DNA amplification and scale-up. These kits enable automated and on-demand synthesis of transfection-scale DNA from customers' own DNA fragments or plasmid DNA. This innovation is expected to significantly reduce the time and steps required for DNA cloning and scaling, enhancing research workflows. Telesis Bio plans to release additional BioXp® kits throughout 2023, which will further improve processes like NGS Library Preparation and CRISPR gRNA synthesis.
Telesis Bio Inc. (NASDAQ: TBIO) reported a record revenue of $9.5 million for 4QFY22, reflecting a remarkable 208% increase compared to 4QFY21. The company's BioXp revenue rose 158% to $3.4 million. Gross margin improved to 68%, up from 29% year-over-year, despite operating expenses increasing to $14.3 million. The net loss narrowed to $8.1 million from $12.5 million the previous year. For 2023, Telesis Bio expects total revenue exceeding $45 million and gross margin between 55% and 59%. The company is focused on strategic investments to drive long-term growth and profitability.
Telesis Bio Inc. (NASDAQ: TBIO) announced that Daniel Gibson, Ph.D., CTO and Co-founder, will present at the Festival of Biologics on March 21, 2023. His talk, titled “Building Biology Overnight”, will focus on overcoming synthesis bottlenecks using hands-free automated synthetic biology solutions, particularly the award-winning BioXp® platform. Dr. Gibson will showcase the new SOLA technology, enhancing DNA synthesis by efficiently assembling complex synthetic genes and mRNA templates through a pre-manufactured library of short DNA oligos. This innovation aims to expedite timelines for applications in vaccine and therapeutics development.